Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: A meta-analysis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Cheng, Hao ^a   Long, Feiwu ^a   Jaiswar, Mukesh ^a   Yang, Lie ^a   Wang, Cun ^a   Zhou, Zongguang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOLOGY; FACTUAL DATABASE; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE; META ANALYSIS; METABOLISM; MORTALITY; NEUTROPHIL; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE;

DATABASES, FACTUAL; HUMANS; LEUKOCYTE COUNT; LYMPHOCYTES; NEUTROPHILS; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 84938503140     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11026     Document Type: Article

References (34)

1. Raimondi S., Maisonneuve P., & Lowenfels A. B. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 6, 699-708 (2009
2. Jemal A., et al. Global cancer statistics. CA Cancer J Clin 61, 69-90 (2011
3. Balkwill F., & Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357, 539-545 (2001
4. Roxburgh C. S., & McMillan D. C. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6, 149-163 (2010
5. McMillan D. C. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 12, 223-226 (2009
6. Hamed M. O., Roberts K. J., Smith A. M., & Morris Stiff G. Elevated pre-operative neutrophil to lymphocyte ratio predicts disease free survival following pancreatic resection for periampullary carcinomas. Pancreatology 13, 534-538 (2013
7. Sanjay P., et al. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. JOP 13, 199-204 (2012
8. Clark E. J., et al. Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma. HPB(Oxford) 9, 456-460 (2007
9. Teo M., et al. Prognostic role of neutrophil-to-lymphocyte ratio in advanced pancreatic ductal adenocarcinoma: impact of baseline fluctuation and changes during chemotherapy. Tumori 99, 516-522 (2013
10. Luo G., et al. Blood Neutrophil-Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with Chemotherapy. Ann Surg Oncol 22, 670-676 (2014
11. Wang D. S., et al. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol 29, 3092-3100 (2012
12. An X., et al. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 15, 516-522 (2010
13. Bhatti I., Peacock O., Lloyd G., Larvin M., & Hall R. I. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg 200, 197-203 (2010
14. Xue P., et al. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Cancer Med 3, 406-415 (2014
15. Martin H. L., et al. Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer. Intern Med J 44, 676-682 (2014
16. Inoue D., et al. Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a single institute in Japan. Jpn J Clin Oncol 45, 61-66 (2014
17. Ben Q., et al. Validation of the Pretreatment Neutrophil-Lymphocyte Ratio as a Predictor of Overall Survival in a Cohort of Patients With Pancreatic Ductal Adenocarcinoma. Pancreas 44, 471-477 (2014
18. Mantovani A., Allavena P., Sica A., & Balkwill F. Cancer-related inflammation. Nature 454, 436-444 (2008
19. Grivennikov S. I., Greten F. R., & Karin M. Immunity, inflammation, and cancer. Cell 140, 883-899 (2010
20. Castelao J. E., Yuan J. M., Gago-Dominguez M., Yu M. C., & Ross R. K. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Bri J Cancer 82, 1364-1369 (2000
21. Daugherty S. E., et al. Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis. Am J Epidemiol 173, 721-730 (2011
22. Calman K. C. Tumour immunology and the gut. Gut 16, 490-499 (1975
23. Nind A. P., Nairn R. C., Rolland J. M., Guli E. P., & Hughes E. S. Lymphocyte anergy in patients with carcinoma. Bri J Cancer 28, 108-117 (1973
24. Ogino S., et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 15, 6412-6420 (2009
25. Waldner M., Schimanski C. C., & Neurath M. F. Colon cancer and the immune system: the role of tumor invading T cells. World J Gastroenterol 12, 7233-7238 (2006
26. Ropponen K. M., Eskelinen M. J., Lipponen P. K., Alhava E., & Kosma V. M. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 182, 318-324 (1997
27. Schreiber R. D., Old L. J., & Smyth M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570 (2011
28. Svennevig J. L., Lunde O. C., Holter J., & Bjorgsvik D. Lymphoid infiltration and prognosis in colorectal carcinoma. Bri J Cancer 49, 375-377 (1984
29. Petrie H. T., Klassen L. W., & Kay H. D. Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol 134, 230-234 (1985
30. Aliustaoglu M., et al. The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer. Hepatogastroenterology 57, 640-645 (2010
31. Sugiura T., Uesaka K., Kanemoto H., Mizuno T., & Okamura Y. Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after gastroenterostomy in patients with advanced pancreatic adenocarcinoma. Ann Surg Oncol 20, 4330-4337 (2013
32. Szkandera J., et al. External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. PloS One 8, e78225, doi: 10.1371/journal.pone.0078225 (2013
33. Stotz M., et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Bri J Cancer 109, 416-421 (2013
34. Garcea G., et al. Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg 35, 868-872 (2011